<DOC>
	<DOCNO>NCT01181154</DOCNO>
	<brief_summary>The hypothesis base retrospective data , rate overall response-rate ( PR + CR ) 1 year much high rituximab arm ( 80 % ) placebo arm ( 20 % ) .Thirty four patient ( 17 arm ) include ( amendment n°6 - 15/10/2013 ) 3 year period ( amendment n°3 - 11/12/2012 ) .</brief_summary>
	<brief_title>Rituximab Auto-Immune Hemolytic Anemia</brief_title>
	<detailed_description>The primary aim study ass efficacy ( overall response rate 1 year ) rituximab ( anti-CD20 monoclonal antibody ) AIHA due warm autoantibody administer initial phase disease . All eligible patent newly diagnose AIHA ( within 6 week diagnosis ) treat corticosteroid standard dose ( prednisone 1 mg/kg/day ) randomize 2 arm : Rituximab placebo 1000 mg day 1 15 1/1 ratio . As soon least partial remission ( PR ) AIHA achieve , daily dose prednisone taper follow rule provide protocol . The hypothesis base retrospective data , rate overall response-rate ( PR + CR ) 1 year much high rituximab arm ( 80 % ) placebo arm ( 20 % ) .Thirty two patient ( 16 arm ) include 2 year period .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . AIHA define time diagnosis Hgb level £ 10 g/dL , reticulocytes count &gt; 120 109/L , sign hemolysis ( least haptoglobin level &lt; 4 mg/L ) , positive direct antiglobulin test ( DAT ) ( IgG IgG + complement pattern ) . 3 . Disease duration equal le 6 week time inclusion &gt; remove amendment n°4 substitute : First episode AIHA `` hot '' antibody previously untreated treated corticosteroid le 6 week . 4 . Patients associated autoimmune thrombocytopenia ( Evans ' syndrome ) eligible study platelet count 30 x 109/L inclusion . 5 . Normal level gammaglobulins serum ( i.e . &gt; 5g/L ) inclusion . 6 . Absence detectable lymph node total body CTscan ( perform inclusion perform diagnosis ) . 7 . Effective mean contraception treatment six month completion treatment woman child bear age 8 . Negative serum pregnancy test within 14 day prior study entry . 9 . Written inform consent Previous treatment rituximab 1 . AIHA diagnose treat 6 week prior inclusion remove amendment n°4 substitute AIHA relapse newly diagnose treated corticosteroid 6 week 2 . Ongoing immunosuppressive therapy ( corticosteroid ) previous treatment administer within 2 week prior begin study treatment 3 . NonHodgkin Lymphoma ( NHL ) stage A chronic lymphoid leukemia 4 . Previous concomitant malignancy basal cell squamous cell carcinoma skin , carcinomainsitu cervix , malignancy patient diseasefree least 5 year . 5 . Autoimmune disorder SLE least one extrahematological manifestation require treatment steroid and/or immunosuppressive drug . 6 . Any associated cause congenital acquire hemolytic anemia ( except thalassemia trait heterozygous sickle cell anemia ) . 7 . Negative DAT DAT positive isolate antiC3d pattern relate presence monoclonal IgM cold agglutinin property . 8 . Positive HIV test and/or hepatitis virus C infection and/or positive hepatitis B virus surface antigen ( HbsAg ) . 9 . Neutrophils count &lt; 1,000/mm 3 inclusion . 10 . Impaired renal function indicate serum creatinine level &gt; 2 mg/d 11 . Inadequate liver function indicate total bilirubin level &gt; 2.0 mg/dL and/or AST ALT level &gt; 2x upper limit normal . 12 . New York Heart Classification III IV heart disease . 13 . Previous history severe psychiatric disorder unable comply study followup procedure 14 . Pregnant lactate woman , woman plan become pregnant within 12 month receive study drug 15 . Absence write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Auto-Immune</keyword>
	<keyword>Hemolytic</keyword>
	<keyword>Anemia</keyword>
	<keyword>AHA</keyword>
	<keyword>AIHA</keyword>
	<keyword>Rituximab</keyword>
</DOC>